128 related articles for article (PubMed ID: 8903974)
1. Conformational aspects of differences in requirements for oxytocin and vasopressin receptors.
Oldziej S; Ciarkowski J; Liwo A; Shenderovich MD; Grzonka Z
J Recept Signal Transduct Res; 1995; 15(1-4):703-13. PubMed ID: 8903974
[TBL] [Abstract][Full Text] [Related]
2. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
[TBL] [Abstract][Full Text] [Related]
3. Non-peptide oxytocin agonists.
Pitt GR; Batt AR; Haigh RM; Penson AM; Robson PA; Rooker DP; Tartar AL; Trim JE; Yea CM; Roe MB
Bioorg Med Chem Lett; 2004 Sep; 14(17):4585-9. PubMed ID: 15357997
[TBL] [Abstract][Full Text] [Related]
4. Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor.
Chan WY; Wo NC; Cheng LL; Manning M
J Pharmacol Exp Ther; 1996 May; 277(2):999-1003. PubMed ID: 8627583
[TBL] [Abstract][Full Text] [Related]
5. Blocking effects of V1 (OPC-21268) and V2 (OPC-31260) antagonists on the negative inotropic response to vasopressin in isolated dog heart preparations.
Furukawa Y; Takayama S; Ren LM; Sawaki S; Inoue Y; Chiba S
J Pharmacol Exp Ther; 1992 Nov; 263(2):627-31. PubMed ID: 1331408
[TBL] [Abstract][Full Text] [Related]
6. Oxytocin and vasopressin stimulate anion secretion by human and porcine vas deferens epithelia.
Hagedorn TM; Carlin RW; Schultz BD
Biol Reprod; 2007 Sep; 77(3):416-24. PubMed ID: 17442854
[TBL] [Abstract][Full Text] [Related]
7. Effects of receptor blockade on metabolism and renal actions of vasopressin in conscious dogs.
Grove L; Christensen P; Bie P
Acta Physiol Scand; 1998 May; 163(1):93-101. PubMed ID: 9648627
[TBL] [Abstract][Full Text] [Related]
8. Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors.
Tahara A; Tsukada J; Tomura Y; Kusayama T; Wada K; Ishii N; Taniguchi N; Suzuki T; Yatsu T; Uchida W; Shibasaki M
Pharmacol Res; 2005 Mar; 51(3):275-81. PubMed ID: 15661579
[TBL] [Abstract][Full Text] [Related]
9. Effects of the non-peptide inhibitor OPC-21268 on oxytocin and vasopressin stimulation of rat and human myometrium.
Atke A; Vilhardt H; Hauzerova L; Barth T; Andersen LF
Eur J Pharmacol; 1995 Jul; 281(1):63-8. PubMed ID: 8566118
[TBL] [Abstract][Full Text] [Related]
10. Effects of a single administration of oxytocin or vasopressin and their interactions with two selective receptor antagonists on memory storage in mice.
Boccia MM; Kopf SR; Baratti CM
Neurobiol Learn Mem; 1998 Mar; 69(2):136-46. PubMed ID: 9619993
[TBL] [Abstract][Full Text] [Related]
11. Analysis of interactions responsible for vasopressin binding to human neurohypophyseal hormone receptors-molecular dynamics study of the activated receptor-vasopressin-G(alpha) systems.
Slusarz MJ; Giełdoń A; Slusarz R; Ciarkowski J
J Pept Sci; 2006 Mar; 12(3):180-9. PubMed ID: 16114100
[TBL] [Abstract][Full Text] [Related]
12. Discovery and optimization of highly ligand-efficient oxytocin receptor antagonists using structure-based drug design.
Bellenie BR; Barton NP; Emmons AJ; Heer JP; Salvagno C
Bioorg Med Chem Lett; 2009 Feb; 19(3):990-4. PubMed ID: 19095447
[TBL] [Abstract][Full Text] [Related]
13. Characterization of receptors mediating contraction of the rat isolated small mesenteric artery and aorta to arginine vasopressin and oxytocin.
Stam WB; Van der Graaf PH; Saxena PR
Br J Pharmacol; 1998 Oct; 125(4):865-73. PubMed ID: 9831926
[TBL] [Abstract][Full Text] [Related]
14. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
Cheng LL; Stoev S; Manning M; Derick S; Pena A; Mimoun MB; Guillon G
J Med Chem; 2004 Apr; 47(9):2375-88. PubMed ID: 15084136
[TBL] [Abstract][Full Text] [Related]
15. Distribution of vasopressin and oxytocin binding sites in the brain and upper spinal cord of the common marmoset.
Schorscher-Petcu A; Dupré A; Tribollet E
Neurosci Lett; 2009 Sep; 461(3):217-22. PubMed ID: 19539696
[TBL] [Abstract][Full Text] [Related]
16. Molecular docking-based study of vasopressin analogues modified at positions 2 and 3 with N-methylphenylalanine: influence on receptor-bound conformations and interactions with vasopressin and oxytocin receptors.
Slusarz MJ; Sikorska E; Slusarz R; Ciarkowski J
J Med Chem; 2006 Apr; 49(8):2463-9. PubMed ID: 16610789
[TBL] [Abstract][Full Text] [Related]
17. Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach.
Oshikawa S; Tanoue A; Koshimizu TA; Kitagawa Y; Tsujimoto G
Mol Pharmacol; 2004 Mar; 65(3):623-9. PubMed ID: 14978240
[TBL] [Abstract][Full Text] [Related]
18. Selective fluorescent nonpeptidic antagonists for vasopressin V₂ GPCR: application to ligand screening and oligomerization assays.
Loison S; Cottet M; Orcel H; Adihou H; Rahmeh R; Lamarque L; Trinquet E; Kellenberger E; Hibert M; Durroux T; Mouillac B; Bonnet D
J Med Chem; 2012 Oct; 55(20):8588-602. PubMed ID: 22984902
[TBL] [Abstract][Full Text] [Related]
19. Exploration of the conformational space of oxytocin and arginine-vasopressin using the electrostatically driven Monte Carlo and molecular dynamics methods.
Liwo A; Tempczyk A; Ołdziej S; Shenderovich MD; Hruby VJ; Talluri S; Ciarkowski J; Kasprzykowski F; Lankiewicz L; Grzonka Z
Biopolymers; 1996 Feb; 38(2):157-75. PubMed ID: 8589250
[TBL] [Abstract][Full Text] [Related]
20. A nonpeptide oxytocin receptor antagonist radioligand highly selective for human receptors.
Lemaire W; O'Brien JA; Burno M; Chaudhary AG; Dean DC; Williams PD; Freidinger RM; Pettibone DJ; Williams DL
Eur J Pharmacol; 2002 Aug; 450(1):19-28. PubMed ID: 12176104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
